iGenomX

San Diego, United States Founded: 2012 • Age: 14 yrs Acquired By Twist Bioscience
NGS library construction solutions are provided to enhance DNA sequencing.
Request Access

About iGenomX

iGenomX is a company based in San Diego (United States) founded in 2012 was acquired by Twist Bioscience in June 2021.. iGenomX has raised $5.13 million across 2 funding rounds from investors including Twist Bioscience. iGenomX operates in a competitive market with competitors including Abcam, Stem Cell Technologies, GenScript, Sino Biological and RareCyte, among others.

  • Headquarter San Diego, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Legal Name Igenomx International Genomics Corporation
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $5.13 M (USD)

    in 2 rounds

  • Latest Funding Round
    $2.11 M (USD), Series A

    Apr 23, 2019

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Twist Bioscience

    (Jun 30, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of iGenomX

iGenomX has successfully raised a total of $5.13M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.11 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $2.1M
  • First Round

    (08 Dec 2015)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2019 Amount Series A - iGenomX Valuation

investors

Dec, 2015 Amount Series A - iGenomX Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in iGenomX

iGenomX has secured backing from 1 investor. Prominent investors backing the company include Twist Bioscience. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Synthetic DNA is synthesized via a semiconductor-based platform.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by iGenomX

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - iGenomX

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Igenomx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of iGenomX

iGenomX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, GenScript, Sino Biological and RareCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Biological reagents and antibodies are developed for life science research.
domain founded_year HQ Location
Developer of cell culture media and ancillary reagents for life science research
domain founded_year HQ Location
Reagents and instruments are provided for life sciences research.
domain founded_year HQ Location
Reagents and kits are provided for clinical research applications.
domain founded_year HQ Location
Developer of technologies for the analysis of rare and single cells in the blood
domain founded_year HQ Location
Immuno-sequencing products are developed for disease diagnostics and treatment.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Igenomx

Frequently Asked Questions about iGenomX

When was iGenomX founded?

iGenomX was founded in 2012 and raised its 1st funding round 3 years after it was founded.

Where is iGenomX located?

iGenomX is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Is iGenomX a funded company?

iGenomX is a funded company, having raised a total of $5.13M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.02M, raised on Dec 08, 2015.

What does iGenomX do?

iGenomX offers low-cost sample preparation technology capable of detecting all genetic variation. The tech was licensed from the laboratory of Dr. Daniel Salomon at the Scripps Research Institute. The low cost, fully automatable methodology centers around precisely controlling the polymerase enzyme to catalyze the formation of long-chain molecules by linking smaller molecular units, such as nucleotides with nucleic acids. This overcomes uncontrolled polymerization which causes amplification bias and error propagation, which leads to increased costs and reduced data quality.

Who are the top competitors of iGenomX?

iGenomX's top competitors include Abcam, Sino Biological and Paragon Genomics.

Who are iGenomX's investors?

iGenomX has 1 investor. Key investors include Twist Bioscience.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available